Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · August 09, 2024

Drug Survival of Omalizumab in Patients With Chronic Urticaria and the Potential Predictors for Discontinuation

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation
JAMA Dermatol 2024 Jul 17;[EPub Ahead of Print], R Soegiharto, M Alizadeh Aghdam, JA Sørensen, E van Lindonk, F Bulut Demir, NM Porras, Y Matsuo, L Kiefer, AC Knulst, M Maurer, C Ritchie, M Rudenko, E Kocatürk, RFJ Criado, S Gregoriou, T Bobylev, A Kleinheinz, S Takahagi, M Hide, AM Giménez-Arnau, A Salman, RO Kara, B Sevimli Dikicier, MBA van Doorn, SF Thomsen, JMPA van den Reek, H Röckmann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading